Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 156,079 229,843 273,203 611,547
Total Sell Value $13,472,349 $20,340,408 $24,241,430 $58,103,504
Total People Sold 5 5 6 7
Total Sell Transactions 13 19 25 55
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 1313
  Page 13 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2021-03-16 4 D $77.21 $44,936 D/D (582) 37,224     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2021-03-16 4 D $77.21 $174,417 D/D (2,259) 108,596     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-03-15 4 D $78.39 $1,836,364 D/D (23,426) 313,576     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-03-15 4 A $0.00 $0 D/D 41,350 337,002     -
   Guyer Charles Greg EVP, Chief Technical Officer   •       –      –    2021-03-15 4 A $0.00 $0 D/D 10,420 45,460     -
   Davis George Eric EVP, General Counsel   •       –      –    2021-03-15 4 D $78.39 $393,047 D/D (5,014) 71,083     -
   Davis George Eric EVP, General Counsel   •       –      –    2021-03-15 4 A $0.00 $0 D/D 10,420 76,097     -
   Acosta Andrea GVP, Chief Accounting Officer   •       –      –    2021-03-15 4 D $78.39 $43,350 D/D (553) 18,515     -
   Acosta Andrea GVP, Chief Accounting Officer   •       –      –    2021-03-15 4 A $0.00 $0 D/D 4,290 19,068     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2021-03-15 4 D $78.39 $413,350 D/D (5,273) 66,728     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2021-03-15 4 A $0.00 $0 D/D 10,720 72,001     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2021-03-15 4 D $78.39 $77,920 D/D (994) 37,806     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2021-03-15 4 A $0.00 $0 D/D 10,110 38,800     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2021-03-15 4 D $78.39 $584,789 D/D (7,460) 110,855     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2021-03-15 4 A $0.00 $0 D/D 15,320 118,315     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-03-12 4 AS $77.10 $539,700 D/D (7,000) 295,652     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-03-12 4 OE $26.49 $185,430 D/D 7,000 302,652     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-03-11 4 AS $77.68 $543,760 D/D (7,000) 295,652     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-03-11 4 OE $26.49 $185,430 D/D 7,000 302,652     -
   Grey Michael G Director   –       •      –    2021-03-05 4 S $76.28 $381,400 D/D (5,000) 42,840     -
   Grey Michael G Director   –       •      –    2021-03-05 4 OE $26.49 $132,450 D/D 5,000 47,840     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-03-04 4 A $77.94 $7,794 D/D 100 295,652     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-02-19 4 AS $83.58 $585,060 D/D (7,000) 295,552     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-02-19 4 OE $26.49 $185,430 D/D 7,000 302,552     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-02-18 4 AS $85.08 $595,560 D/D (7,000) 295,552     -
  1313 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 13 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us